Last reviewed · How we verify
NCT07280793
CAR-T Cell Efficacy With Molecular Imaging in Multiple Myeloma
EARLY_PHASE1 trial testing BCMA-Targeting CAR-T Cell Therapy in Non-invasive CAR-T Cell Monitoring in 10 participants. Not yet recruiting.
30 December 2027
Quick facts
| Lead sponsor | Xuzhou Medical University |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 17 December 2025 |
| Primary completion | 30 December 2027 |
| Estimated completion | 30 December 2027 |
Drugs / interventions tested
- BCMA-Targeting CAR-T Cell Therapy
- PET/CT Imaging
Conditions studied
- Non-invasive CAR-T Cell Monitoring — all drugs for Non-invasive CAR-T Cell Monitoring →
- BCMA-targeted PET Imaging — all drugs for BCMA-targeted PET Imaging →
- CAR-T Cell Biodistribution and Persistence — all drugs for CAR-T Cell Biodistribution and Persistence →
- GMP-compliant Radiopharmaceutical Preparation — all drugs for GMP-compliant Radiopharmaceutical Preparation →
Sponsor
Xuzhou Medical University
Who can join
Adults 18 to 75, any sex, with Non-invasive CAR-T Cell Monitoring or BCMA-targeted PET Imaging. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
⁶⁸Ga-NOTA-BCMA is a novel, targeted PET tracer under clinical investigation. It is designed to provide a non-invasive method for monitoring the biodistribution and persistence of BCMA CAR-T cells in patients. Preclinical data robustly support its specific binding, favorable pharmacokinetics, and excellent safety profile, warranting its advancement into clinical studies.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07280793
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Xuzhou Medical University trials
Trials by the same sponsor.
- NCT07370064 — Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia · Phase 1, PHASE2 · not yet recruiting
- NCT07070960 — A Study of Anti-BCMA CAR-T Therapy in Newly Diagnosed Myeloma Patients Who Are Transplant-ineligible · NA · not yet recruiting
- NCT07070934 — CAR-T vs. Auto-SCT: Which Works Better for New Myeloma Patients? · Phase 2 · not yet recruiting
- NCT06963866 — Comparing ASCT Followed by Anti-BCMA CAR-T vs. ASCT Alone in NDMM Patients Eligible for ASCT · Phase 2 · not yet recruiting
- NCT06913192 — Efficacy of Sequential BCMA CAR-T Cell Therapy Following Autologous Hematopoietic Stem Cell Transplantation in Transplan · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07280793 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xuzhou Medical University
- Last refreshed: 17 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07280793.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing